MedLumics

Founded 2009
Employees 20+
Primary contact
Plaza de la Encina 10-11 Núcleo 3 2ºA
Tres Cantos
28760 Madrid
Spain
(+34) 91 803 39 25
MedLumics develops a radiofrequency cardiac ablation catheter called AblaView, which allows the treatment of atrial fibrillation (AF) in real time using an optical image guidance system. Said treatment relies on a minimally-invasive surgical technique that involves scarring or destroying tissue in the heart using radiofrequency energy to disrupt faulty electrical signals causing the arrhythmia. It is based on the technology known as optical coherence tomography (OCT), which uses optical waves to generate a high-resolution, cross-sectional view of the tissue. During the procedure, catheters are inserted with a needle into a vein that runs from the groin into the left atrium of the heart, guided using a continuous X-ray imaging procedure known as fluoroscopy. By measuring the electrical signals in the chamber, doctors can tell where short circuits leading to AF are occurring and cauterize them.
Founded 2009
Employees 20+
Primary contact
Plaza de la Encina 10-11 Núcleo 3 2ºA
Tres Cantos
28760 Madrid
Spain
(+34) 91 803 39 25

Funding 💰

Total €60.7M
Select investors Caixa Capital, Ysios Capital, Andera Partners, Asabys Partners, Innogest Capital, Seroba Life Sciences, VI Partners, Kurma Partners, CDTI

Key people 🧑‍🤝‍🧑

Highlights

  • Big addressable market: Atrial Fibrillation (AF) is the most common type of cardiac arrhythmia, currently affecting an estimated 33 million people worldwide. AF recurrence remains high with more than 20% of patients undergoing repeat ablation within one year of initial treatment. Addressing an unmet clinical need, AblaView is the first imaging system to directly assess lesion creation, allowing the operator to confidently ascertain the stability of the contact and the positioning of the catheter on the atrial wall. 🔗
  • Powerful tech: MedLumics' AblaView uses Optical Coherence Tomography (OCT), which a light-based imaging technique that has established itself by delivering higher resolutions than MRI and ultrasound.
  • Better procedures: MedLumics says its device improves AF treatments by using OCT to provide more accurate readings on the distance to the blood vessel wall, how well it is making contact with the lesion, and measuring the amount of damaged tissue. It also thinks this will allow the procedure to be performed more accurately, causing less unneeded tissue damage, and that in turn could reduce the risk of AF recurring.

Video ▶️

Quotes 💬

The Medlumics technology has the potential to greatly enhance clinical outcomes by providing real time feedback on constant contact of the ablation and visual display of the depth and conductivity of the tissue.
Rich Ferrari, investor 🔗
We have seen an intensive and exciting period between 2017 and 2020, in which Medlumics has masterminded technically one of the most difficult to accomplish challenges in the electrophysiology lab by delivering a catheter which is capable of performing real-time lesion assessments during AF ablation.
Olivier Litzka, Partner at Andera Partners 🔗
We are excited to work with MedLumics in developing a truly innovative technology, a potential game changer in the interventional treatment of Atrial Fibrillation, a multi-billion-euro market opportunity. Patient outcomes will be dramatically impacted by the ability of clinicians to follow in real time the progression of ablations and their quality. We are happy to be joining this talented team and our syndicate partners, in supporting MedLumics' evolution into a successful international business.
Peter Neubeck, Partner at Kurma Partners 🔗
Last update: January 13, 2023